BioCentury’s latest Deals Report also includes Regenxbio/Nippon, Merus/Biohaven and Daiichi Sankyo/Glycotope

If fulfilled, CVR tied to pipeline programs would drive deal’s value even further

In wake of AstraZeneca deals, Japanese pharma partners three more ADC candidates, this time in a Merck transaction worth up to $22B

BioCentury’s analysis of the AACR 2023 abstracts highlights innovation in antibody-drug conjugate design

Same targets, but more stringent patient selection protocols and optimized cell engineering

Emerging Company Profile: Ireland’s ONK Therapeutics soups up CAR NK cells with TRAIL variants

The targets and indications CAR T developers are exploring to get to efficacy in solid tumors

How Tmunity’s focus on CMC for its engineered T cell therapies factored into its $75M series B